Thank you for standing by and welcome to the Health Catalyst Third Quarter 2021 Earnings Conference Call. [Operator Instructions] As a reminder, today’s program is being recorded. And now I’d like to hand the program over to Adam Brown.

Good afternoon and welcome to Health Catalyst’s earnings conference call for the third quarter of 2021, which ended on September 30, 2021. My name is Adam Brown. I am the Senior Vice President of Investor Relations and Financial Planning and Analysis for Health Catalyst. And with me on the call is Dan Burton, our Chief Executive Officer and Bryan Hunt, our Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today as well as in our related Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. As a reminder, today’s call is being recorded and a replay will be available following the conclusion of the call. During the call, we will make forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, regarding trends, strategies, the impact of the COVID-19 pandemic on our business and results of operations, our pipeline conversion rates and our general anticipated performance of the business. These forward-looking statements are based on management’s current views and expectations as of today and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to update any forward-looking statements or outlook. Actual results may materially differ. Please refer to the risk factors in our Form 10-Q for Q2 2021 filed with the SEC on August 6, 2021 and our Form 10-Q for the third quarter of 2021 that will be filed with the SEC today. We will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of these non-GAAP financial measures to their most comparable GAAP measures is provided in our press release. With that, let me turn the call over to Dan for his prepared remarks and then Bryan will subsequently provide his prepared remarks. Dan and Bryan will then take your questions. Dan?

Thank you, Adam and thank you to everyone who has joined us this afternoon. We are excited to share our third quarter 2021 financial performance, along with additional highlights from the quarter. I will begin today’s call with some commentary on our third quarter 2021 financial results by sharing that we are pleased with the company’s overall financial performance. Our Q3 2021 total revenue was $61.7 million and our adjusted EBITDA was a loss of $5.8 million, with these results beating the midpoint of our quarterly guidance on each metric. Additionally, our Q3 2021 technology revenue was $38.3 million, representing 37% growth year-over-year, and our Q3 2021 adjusted technology gross margin was 69.9%, representing an increase of approximately 150 basis points year-over-year. Now let me highlight some additional items from the quarter. You will recall from our previous earnings calls, that we measure our company’s performance in the three strategic objective categories of improvement, growth and scale. And we will discuss our quarterly results with you in each of these categories. The first category improvement is focused on evaluating our ability to enable our customers to realize massive, measurable improvements while also maintaining industry-leading customer and team member satisfaction and engagement. Let me begin by sharing a couple of examples of customer improvements from recently published case studies. First, Carle Health and its affiliated Health Alliance health plan struggled with a largely manual approach to its population health and value-based contracting initiatives. In response, Carle and Health Alliance leveraged our DAS data platform and our new value optimizer analytics application, which we introduced on our last earnings call. This software allowed Carle to have real-time insight into a multitude of cost utilization and performance metrics from across 10 key population health areas, including inpatient and skilled nursing facility readmissions, inpatient…

Thank you, Dan. Before diving into our quarterly financial results, I want to echo Dan’s sentiment and say that I am pleased with our third quarter 2021 results. I will now comment on our strategic objective category of scale. For the third quarter of 2021, we generated $61.7 million in total revenue. This represents an increase of 31% year-over-year and was an outperformance relative to the midpoint of our guidance. This outperformance was driven mainly by new contracts signing earlier in the quarter than forecasted. Technology revenue for Q3 2021 was $38.3 million, representing 37% growth year-over-year. This year-over-year growth was driven primarily by recurring revenue from new customer additions, from existing customers paying higher technology access fees as a result of contractual built-in escalators as well as from our Vitalware acquisition that closed September 1, 2020, and our Twistle acquisition that closed on July 1, 2021. In Q3, Twistle contributed $1.4 million of technology revenue, inclusive of a purchase accounting-related deferred revenue write-down, which was in line with our expectations shared on our last earnings call. Professional services revenue for Q3 2021 was $23.5 million, representing 22% growth relative to the same period last year. This year-over-year performance was primarily due to our professional services being provided to new DOS subscription customers along with a small amount of COVID-related temporary customer discounts that’s billed into the third quarter of 2020, creating a more favorable year-over-year comparable. Also in line with the expectations we shared on our last earnings call, Q3 2021 professional services revenue was lower than our Q2 2021 revenue, given the modest amount of incremental nonrecurring project-based professional services revenue that we recognized in Q2 2021. Total adjusted gross margin for the third quarter of 2021 was 50.9%, representing an increase of approximately 20 basis points year-over-year.…

Thanks, Bryan. In conclusion, I would like to recognize and thank our highly engaged team members. Without their consistent contributions to our mission and growth, none of this would be possible. And with that, I will turn the call back to the operator for questions

[Operator Instructions] Our first question comes from the line of Anne Samuel from JPMorgan. Your question, please.

Hi, guys. Congrats on a great quarter and thanks for taking the question.

Ma’am, you may have your phone on mute?

We can hear you, Anne.

Okay, great. At your Healthcare Analytics Summit, value-based care was a really big theme. And was wondering, are you finding that the pace of change is accelerating there? And are you seeing more demand from your clients in that area?

Yes, great question, Anne. That was a major theme of the healthcare analytics summit, and that was data informed based on our interactions with both clients and with prospects, and in seeing a meaningful increase in interest and specific focus on value-based care and population health topics in general. And so that focus it has was informed by that data, and we continue to see an uptick in an acceleration both with existing clients and with prospective clients as it relates to that being one of the primary focus areas right now in the market.

The thing I would add, Anne, is that this has been an area that we’ve been thinking about and focusing on over the last several quarters in terms of our development strategy and our acquisition strategy as well. So you’ve seen recent acquisitions there with our healthfinch acquisition a year ago and then the most recent acquisition of Twistle, just in July, which helps to round out our population health suite of applications in a space, patient engagement specifically that continues to be a focus for our health system customers and process. So we’re encouraged by that alignment.

That’s great color. And then maybe one, we’ve been hearing a lot about labor inflation and shortages this quarter from probably some of your customers. Are you doing anything to help them your customers with finding solutions to mitigate some of that impact?

We are. And specifically, our power labor application suite, which we talked about in the last earnings call, is very helpful as it relates to the management of the labor force in specific areas where our health system clients are facing shortages and need to optimize in very specific ways. So that technology solution as well as our deep domain expertise services have been highly utilized by our clients and helping them make it through this challenging environment.

That’s great to hear. Thanks, guys.

Thanks, Anne.

Thank you. Our next question comes from the line of Ryan Daniels from William Blair. Your question please.

Hey, guys. This is Jeff [indiscernible] on for Ryan Daniels. Congrats on the quarter and the continued success, and thanks for taking the question. I guess kind of keeping on the trend of the labor pressures. And I think I believe last quarter, you even mentioned the slower hiring than anticipated. But you don’t expect that to pick up in the back half of the year. So I guess do you have any additional color on the labor pressures and kind of just how has that been trending so far in the second half? And I know to in the prepared remarks, you mentioned one-time bonuses. So any additional color here is really appreciated. Thanks.

Yes, absolutely, Jeff. So – as we alluded to in the prepared remarks, we did see some catching up as it relates to specifically our professional services hiring in this last quarter. We had referenced that we were behind in our last earnings call. So we’ve seen some catching up. And we continue to see this current environment as a very tight labor market environment. And so we’re cognizant of that. That’s an important factor as we think about Q4 in the near-term. And as it relates to what we referenced in terms of one-time bonuses to recognize our team members’ engagement and strong performance. And it will be an important component as we think about our planning process as we do every year for next year for 2022. As you all know, we put team members at the center of everything that we do and their engagement drives our success. And so we want to make sure that we’re always optimized as it relates to our team members and their engagement.

The only thing I would add, Jeff, is that even with some of those delays that Dan referenced earlier in the year, we don’t anticipate and shared previously that we don’t – didn’t anticipate any material impacts to our product development road map, and our ability to execute against that in 2021 or our ability to kind of deliver on our bookings expectations that we mentioned in the remarks. So no major impact to those.

Awesome. Thanks for that info. And then I guess just as a follow-up, I kind of want to pivot towards the Twistle acquisition and just kind of how the integration is going. So I know you mentioned last quarter that one of the early phases for integration was kind of from a sales and marketing standpoint. Can you guys provide any additional color on how the integration is progressing? That would kind of be helpful. And I guess also as we think about the integration, how should we think about the contribution to guidance? I know you mentioned $3 million in EBITDA loss expected. But kind of how is that tracking relative to the plan? And I know – I think you said $1.4 million of tech revenue. So anything is helpful here. Thanks.

Yes. I’m happy to share a few comments and then, Bryan, please share as well. So as it relates to how the integration is going, I’m pleased with where we are relative to our integration goals and how we had forecasted, where we would be I’ll highlight, I had an opportunity recently to travel to Albuquerque, which is the headquarters of Twistle, and we have an office there and spend time one-on-one with many of the Twistle team members. And we continue to be really impressed and excited with the talent level and the expertise in the area of patient engagement, which is so relevant for pop health and other areas of Health Catalyst focus as well in terms of clinical improvement, clinical analytics work as well as our life sciences use cases. So we’re excited about the level of integration. We are seeing very meaningful interest among our existing DOS subscription clients to find out more about Twistle. I’ve personally been asked unprompted by a number of C-suite executives at our existing clients to tell me more about Twistle. And obviously, patient engagement is a very important capability and capacity that our health system clients want to have. So we’re excited about that. And I’ll let Brian comment about the financial impact of Twistle.

Yes, certainly. So in 2021, Jeff, we did mention on the last call that Twistle would contribute about $3 million of mostly technology revenue for the second half of the year, inclusive of a deferred revenue write-down on the top line and then approximately $3 million of adjusted EBITDA burn in the second half of the year as well. When you think about going forward into 2022, on the top line, we had shared at the time of the acquisition that you could think about 2021 stand-alone revenue for Twistle of about $8 million and then growing approximately 35% in 2022. And then on the EBITDA side that we anticipated $2.5 million to $3 million of negative EBITDA contribution in 2022 on top of our kind of core business, inclusive of some integration-related expenses that we will execute on through next year.

Awesome. Thanks, guys.

Thank you. Our next question comes from the line of Jessica Tassan from Piper Sandler. Your question please.

Hi, thank you so much for taking the question. So I think I just wanted to verify, does the mid-teens DOS adds for the year, does that refer to the kind of all-access DOS subscription and services customers that we’ve historically seen?

Yes, it primarily does. And with the note that as we’ve discussed in prior earnings calls, when we defined what is included in that All Access subscription there have always been certain things that are excluded. And importantly, elements like new technology that come to us through acquisitions are outside of that technology subscription. And so when we perform an acquisition, there is an incremental revenue opportunity. But when we talk about the mid-teens to DOS adds that incorporates that idea of a subscription-based model where they can access both DOS and some application capabilities as well.

Understood. So as you think about your existing – All Access subscriptions, should we think about the technologies you’ve acquired year-to-date as being layered in or maybe incremental to that 7% to 9% annual price appreciation?

Yes, they would represent incremental growth opportunity from that contractual built-in – those contractual built-in escalators on the technology side.

Right. And we also – and Jess, part of the thesis there of acquiring at the application layer is one, as Dan mentioned, to have a broader portfolio to sell into our current DOS customer base and expand over time, but also to develop more places to land and meet a new customer prospect where they’d like to start from an analytics standpoint. And so that breadth of the portfolio helps on both of those growth drivers.

Got it. And if I could just sneak in one quick just follow-up. I guess, how much of the base have you gone through in terms of renegotiating the All Access subscriptions to account for the solutions you’ve acquired year-to-date? Thank you.

So that’s really rolling topic of discussion. And mostly, that happens as we acquire a new technology. So less of that happens at the end of a contract period and more happens during the course of the relationship as we acquire a new technology, then typically within 6 months, we will have a discussion with our existing client base about their interest level in that newly acquired technology.

And we are seeing Jess and anticipated to see in 2021 a moderate amount of contribution, in particular on our expansion metrics, where we’re able to cross-sell an application to a DOS subscription customer. And that is – it’s a lower price point, and it is a faster sales cycle than the other direction of selling DOS into an app customer, but we’ve seen some early success there, which we’re encouraged by.

Thank you again.

Thank you.

Thank you.

Thank you. Our next question comes from the line of Elizabeth Anderson from Evercore. Your question please.

This is Joe on for Elizabeth. I just want to ask a quick question on the life sciences offering that you guys hosted a webinar on a few weeks ago. Just wondering, in general, kind of who you see that offering sort of competing with? Is it competing with CROs? Is competing with another player in the space? And then on top of that, what tends to differentiate those solutions in the space? Thanks.

Yes. Thank you for that question, Joe. So as we think about the solution and the offering that we are able to bring to life sciences companies, we are excited about the possibility and the potential but we’re very, very early on. And as we’ve described in prior earnings calls, we recognize there is a great deal that we’re learning about this new market, this adjacent market. And one of the elements that helps us in that regard is to often partner with or complement another larger player like a CRO or another life sciences oriented company where we can provide part of the overall solution, but then benefit from the experience base of another player. So I would think of us as more complementing and strengthening a solution of some established players, especially as we’re early in this adjacent market.

Just in terms of where we aim to differentiate, one aspect is we do as part of our DOS, customers are able to contribute data from DOS, a subset of that data into the identified centralized platform. And that data is very rich in terms of the breadth of clinical data and the depth of that data and the touch points across patients that, that data represents. And so we do think that, that data asset is a strength in terms of how we differentiate against other vendors, as Dan mentioned, coupled with our ability to build analytic applications on top of that data with the intent to drive improvement in any area that we’re working on with life sciences company.

Great. Thank you.

Thank you. Our next question comes from the line of Stephanie Davis from SVB Leerink. Your question please.

Hey, guys. Thank you for taking my question. I was going to pivot away from some of these labor shortage questions and ask some questions about that new strategic end market you guys are going for. So just another flavor of labor questions, but can you just tell us a little bit more about the pharma life sciences strategy and what sort of headcount build-out you would need to target for new arena? Is it primarily going to be sales folks? And sales teams and managers are more familiar with pharma end markets or are we going to see more of an R&D lift as well in order to get you bigger in that market?

Yes. Thank you for the question, Stephanie. So I think it’s both. We need to build and strengthen our capacity as it relates to understanding go-to-market, understanding the end user understanding the use cases. And then we’ve also recognized and learned over the last couple of years that we’ve started to modestly invest here that there is some incremental R&D needed to take that core set of capabilities that is leverageable and that we are excited that we do believe we see evidence of some differentiation, but that there is some incremental R&D needed to suit the specific use cases of these life sciences companies. As you might imagine, in our core market, there isn’t complete overlap between the kinds of use cases that we’ve been focused on, particularly as it relates to clinical improvement, pop health, operational and financial improvement of a health system and then having that translate into contributing to data-informed registries or the support of specific clinical trial recruitment or real-world data at real-world evidence use cases. So we are recognizing the need to continue to make some investments from an R&D perspective and as I mentioned just a few minutes ago, we’re benefiting from learning from partners who have been in this space longer than we have and learning through the hiring of experienced team members as well. But as we’ve shared many times, we’re early in our investments in these adjacent markets, we’re playing the long game as it relates to trying to build something that will be meaningful long-term. But that takes time, and we’re still very early stage in that process.

Understood. The biggest tragedy of real-world evidence of science, a really hard time pronouncing it, it sounds like I’m not the one that I’m not alone in that one.

Yes, we share that. Yes.

I hear you. I hear you. Keeping in mind that buying assets in this very sexy sliver of the market right now is an incredibly high multiple prospects. Should I read into that and assume you guys will do more of a build versus buy as you expand to the side of the market or do you think there is enough opportunity that could justify the prior higher price tag for this?

Yes, it’s a great question. So – as we’ve shared in the past, we include adjacent markets as one of the areas that we pay attention to from an M&A perspective. And we’ve also shared multiple times in the past, we believe in a disciplined process from a financial perspective, and we want to maintain that discipline. And so when there are opportunities in adjacencies, whether that’s in life sciences or in international, we do consider them. We carefully study them, and we apply the same discipline from a framework – a financial framework perspective that we apply across the board. And we think that’s the right long-term strategy. So if there are opportunities that fit within that framework, we will be pursuing them. If not, then we will find other ways through our own investments to continue to build momentum in these adjacent markets.

Looking forward to see that you have built out. Thank you.

Thanks.

Thank you.

Thank you. Our next question comes from the line of David Grossman from Stifel. Your question please.

Thanks. Good afternoon. I’m wondering if we could just go back for a minute just to the services gross margin and perhaps you could just dimension of the three things that you mentioned, which are most impactful for the margins in the back half of the year? And then secondly, to what extent can you pass through some of the more labor-related costs like benefits and we’re just wondering just how much flexibility in magnitude you have in passing that through?

Yes. Thanks, David. So good question. So we do – we have seen over the last couple of years, some fluctuation in our professional services gross margin on a quarterly basis, much more so than our Technology segment as an example. And there are three primary factors that I mentioned in the prepared remarks that can contribute to that fluctuation. So just to kind of dig into those further. The first is that utilization rate of our team members, which, as we’ve described, is a little higher than we would have anticipated in the first half of the year and has more normalized now. The second is the shift in mix of services that we provide. So some services are lower margins, some are higher like our consulting services and analytics services and that can fluctuate on a quarterly basis. And then the last was, to your point, kind of team member related costs like medical and other costs. You can think about the Q3 impact as being a few percentage points related to the labor-related costs that I mentioned on the prepared remarks. And then the remainder of that change being the other two factors, the utilization rate and the mix shift, that’s how I describe Q3 as we kind of look forward to your point on kind of pricing power and passing that through, that’s something that we’re trying to think through and assessing over Q4. We have enough visibility now to provide that color that I mentioned on Q4 gross margin looking similar to Q3 just based on the mix that we see and our current cost profile, but that is something that we’re thinking through as it relates to 2022. So we will continue to provide updates there as we get more data in terms of the price points and then also the cost of per team member that we’re seeing going into next year.

And the only thing I would add, David, is we continue to strive to be data-informed as we are trying to understand pricing changes and pricing input changes that we anticipate, as many others have shared from an economic – a macroeconomic backdrop perspective that some of the pricing increases will be transitory, others may be more long lasting. But we are trying to study that data and be as informed as possible as we think about our own pricing strategy moving into 2022.

Great. Thank you for that. And then another so much forward-looking question, as I recall, your first tranche of customers at the first tranche, but the kind of first tranche, if you will, in the existing area kind of renew, I think start renewing over the next 12 months. And this may have come up in an earlier question, but – just curious with the increased portfolio of apps kind of going in your favor and perhaps the automatic escalators maybe not being as present in the renewals. How do you want us to think about it, or what are you targeting in terms of what you think the retention rate will look like on renewals vis-à-vis where it’s been historically?

Yes. I am happy to comment on that. So, one element that’s important to remember is that in the way that we structure all of our relationships with all of our clients every year, any client who wishes to can always opt out of their relationship, including the technology subscription relationship. And so there isn’t a significant buildup of contracts coming up in any given point in time, every year, they all cycle through that opportunity. And so that’s been a helpful mechanism for us to stay on our toes and make sure that each one of our clients is really receiving great value. And by doing that, we have seen that robust historical dollar-based net retention, particularly as it relates to the technology business, remaining robust all the way through the pandemic through today, and we anticipate that it will continue to be robust at those historical levels as well. And I think as it relates to discussions about moving forward, as Bryan mentioned a little bit earlier, there is a modest amount. And we have mentioned this in prior calls as well of some of that cross-sell of those newly acquired technology capabilities that would fall outside of the traditional subscription, built into our forecast for 2021. And over-performance of that modest amount of cross-sell would represent upside to the way that we forecast and model in 2021 and beyond.

Just to add to that, David. So, we have seen, to your point, some of those contracts with the kind of a 3-year to 7-year original term and ramp coming up for renewal. As Dan mentioned, the things that are helping with that are the broader portfolio, so the cross-sell opportunity with those new applications. The only thing I would mention is that we do also have typically a contractual constraint on the amount of data and the computing power that our hosted environments for DOS can – at which they can perform. And as customers continue to grow and add data and go beyond that, there is an expansion mechanism even for those all access customers as well. So, that’s – that has helped us continue to drive that on average, similar dollar-based retention rate that you have seen historically.

So, just activity levels alone will generate some same-store sales growth is what that last comment refers to?

There is a mechanism for that as well. Yes.

Right. Got it. Okay. Very good. Thanks very much.

Thanks David.

Thank you. Our next question comes from the line of Daniel Grosslight from Citi. Your question please.

Hi. Thanks for taking the question. As you move further into Pop Health, this sales cycles, have you seen more traction outside of traditional health systems, i.e., with payers or risk-bearing providers? And have you had to invest in additional sales resources as you move outside the health system market?

Yes and yes, Daniel. We are seeing generally increased interest in Pop Health offerings, and we are seeing that interest in broader places than just the core health system client or prospect environment. And so as part of our response to that, it’s been helpful for us to expand our capacity and our capabilities there. One of the case studies that we referenced in our prepared remarks includes a good example of that where in our relationship with Carle Health included in that relationship is a meaningful payer capability with their health alliance organization. And we continue to benefit as a company from those experiences where we are working more directly with organizations broader than a traditional health system. And then that informs our population health roadmap. That also informs our go-to-market messaging and strategy and helps us continue to expand.

Okay. Got it. Very helpful. And then similar to David’s question on professional services gross margin, I understand you are not guiding yet to 2022, but I was wondering if directionally you could help us out on how we should think about that over the next 12 months to 18 months? Do you anticipate getting back to the 30s or kind of the 2019 level, or is there really more of a structural shift here that will keep you in the kind of mid to high-20s for some time?

Question, it is something that we are considering and thinking through and assessing that data on through the rest of the year. So, we are not entirely ready yet to kind of make any to your point, more formal 2022 color or guidance as it relates to professional services gross margin. I did mention there is some of that impact that we saw in Q3. Some of that could be more run rate, some could be more one-time in nature. There is also in Q4 an impact to our margin related to the outsized team member compensation and bonuses that we described. Some of that will also impact our professional services gross margin that’s more one-time in nature. So, we will have more visibility as we get through the end of the year. And in particular, assess at the beginning of next year, what mix of services have we sold in Q4, what that mix looks like in our first half 2022 pipeline, the utilization rate of our team members and that’s really what will drive that guidance and color that we will provide in 2022. And then in terms of the long-term professional services target of mid-30s or no update to that at this point in time, something that we are, again, assessing and looking through over the next couple of quarters.

The only thing I would add would be just when we think about the role of professional services at Health Catalyst and the purpose of our professional services, as we have mentioned a number of times in previous calls, we think of that as really being focused on providing the right mix of services that enable our clients to measurably improve. And when that – when what they need changes based on what we are working on together, we optimize in favor of those measurable improvements, which can mean that the mix shifts meaningfully. And you have certainly seen that throughout the past 10 quarters that we have reported as a public company. And we anticipate that, that will continue to be a dynamic that we are optimizing first and foremost, for what our customers need in order to measurably improve. And we allow those needs to really dictate the kind of mix that we offer up to those clients. And we think that’s the right long-term strategy.

Yes. It makes sense. Thanks guys.

Thank you. Our next question comes from the line of Sean Dodge from RBC Capital Markets.

Hi, good afternoon. This is Thomas Keller on for Sean. Thanks for taking the questions. So, I want to talk about the lighter DOS offering. And correct me if I am wrong here, you all have been working on that type of offering prior to the pandemic, but accelerated sort of COVID-specific version that you were selling at a discount. And so my question is, how many of those are in use and are you all continuing to offer a light version of the platform? And has that offering evolved?

Yes. Happy to comment on that, Thomas. So, as you mentioned, we had begun conceptualizing the idea of a lighter DOS offering before the pandemic. As the pandemic hit in the spring of 2020, we accelerated some of our thought processes there and some specific use cases there that were most relevant for a response to the pandemic. And we have continued to evolve and develop and refine that thought process. We do believe that enabling a lower price entry point for our clients to begin a relationship with Health Catalyst is a good long-term strategy. We have seen a few successes in that regard, and we are encouraged to see more representation in our pipeline. As it relates to this lighter offering and coupling that lighter offering with specific use cases at the apps layer, which we have more of now through the introduction of our own built capabilities as well as through some of our M&A activities certainly is encouraging to us. We have built in a modest amount of that capacity and that capability into our forecasting and more than a modest amount like we have talked about before, of success there would represent some upside to our forecasting.

And so just to clarify, the mid-teens DOS target does include some lighter options?

At a modest level, yes.

Okay. That’s helpful. That’s all for me. Thank you.

Thanks Thomas.

Thank you. Our next question comes from the line of Iris Long from Berenberg.

Hi. Thanks for taking my question. So first, a question on pricing and escalator. So, I am wondering in this inflationary environment, how are you thinking about pricing for your solutions in general? Are you going to – and would you be able to raise the price for some of the existing contracts? And then I guess for the newer contracts, are you able to increase the amount of the escalators?

Yes. Thank you for the question, Iris. So, as you may recall, we have shared previously that on the technology subscription side, we do have built-in pricing escalators with those clients that have a subscription offering with Health Catalyst that includes DOS and some meaningful application access that are built in double-digit percentage increases. And so those are already meaningful built-in expansion opportunities for us. And we have been pleased to see that clients have accepted and chosen to continue to renew. And then in addition to that, we have some opportunity for additional expansion through the acquired technology that have come to us through M&A. As it relates to the way that we think about our existing contracts, on both the technology side and the professional services side in the context of inflation. As I mentioned just a few minutes ago, I think we are continuing to study the data, and we are continuing to try to more deeply understand, which components of price and price increase that we are experiencing are transitory and which components are more long lasting to inform the way that we think about pricing. And we are still gathering data. We want some more time and space to understand that data before we make any specific decisions as it relates to 2022 and beyond.

Got it. I appreciate your insight there. And then I guess a similar question on margins. How are you thinking about the margin expansion opportunity from the Q3 level? I am also wondering, do you continue to expect breakeven on adjusted EBITDA from next year?

Yes. Thanks, Iris. So, in terms of the gross margin dynamics, so I would share, consistent with what we shared over the last couple of quarters, first on the Technology segment. Our technology gross margin has ticked up over the last couple of years to the high-60s year-to-date, and we do expect that to be the case over the next few quarters as well. Technology gross margin is typically on a per customer basis expanding over time. As our technology revenue grows at a customer level, but our hosting and support costs don’t grow at the same rate. However, that is offset by a headwind that we have of migrating some customers who are on-premise to a hosted solution, which adds technology. So, that’s the technology gross margin dynamic I would share. On the professional services side, I mentioned in the prepared remarks, but we have enough visibility into the Q4 professional services gross margin profile to be roughly in line with Q3. And then we are assessing, as I mentioned, kind of the 2022 impact on that, and we will provide updates there early next year. And then in terms of our EBITDA trajectory, so I would just remind what we have shared publicly in prior conversations, where we had expected our core business to begin 2022 on our run rate adjusted EBITDA breakeven basis. And then with the Twistle acquisition, we shared that we expected Twistle to contribute $2.5 million to $3 million of incremental EBITDA losses in 2022. And at this point in time, we are not providing any specific updates or guidance or commentary related to 2022 EBITDA guidance and color. Main reasons for that is we are still working through at this point in the year, our planning process and budget cycle. There are a lot of variables that go into that planning process, our Q4 bookings performance, our first half sales pipeline, the – as Dan mentioned, taking through areas of investment across growth and R&D and other factors. And so typically, we don’t share kind of specific guidance on that metric until we get into the beginning of next year.

And Iris, I might just add a couple of additional thoughts. So, one element that we shared in the last earnings call that was certainly exciting for us as a company was that the company did achieve in Q2 and in actually the first half in total, adjusted EBITDA positive territory. And so that was an exciting milestone to get to a little earlier than what we had described in terms of our timeline when we went public and in terms of what Bryan just shared in terms of the thought process of beginning 2022 on an adjusted EBITDA breakeven run rate. And certainly, we shared with you all that there is seasonality in our business, and there are some specific expenses that hit like the Healthcare Analytics Summit expense that happens in the – in the back half of each year. So, certainly for this year, that applies. I would also share as we think forward and as Bryan mentioned, as part of the planning process for 2022, some of the highest priority items for me definitely include our financial sustainability as a company. They also include important R&D investments that we are very excited about making that that can help us long-term to accelerate our growth and opportunities before us. I am also sensitive, as we have discussed and as a few individuals have brought up in their questions, the very tight labor market that we have, and we are taking some specific actions in Q4 here. We want to be mindful of our team members as it relates to the 2022 planning process and ensuring that our compensation practices for our team members are positive and favorable and competitive as we have benefited so much from team member engagement, team member retention, very low turnover rates, and we want that to continue to be the case at Health Catalyst as well. So, I am thinking about a number of priorities. As Bryan shared, we are in the midst of that even early in the planning process for 2022, but by our next earnings call, we will be in a good position to share more of an update as it relates to how we think about 2022.

Got it. Thank you so much for the color.

Thanks, Iris.

Thank you. Our next question comes from the line of David Larsen from BTIG. Your question please.

You mentioned a couple of times that in the services area, the utilization rates normalized. So, what I am assuming that means is earlier in the year, your consultants were very busy billing 40 hours or 50 hours a week. And those utilization rates have slowed. Is that correct? And what drove that? What were they working on earlier in the year? What was the nature of the demand, if you will? And what has changed or evolved as we get into 3Q here?

Yes. Thank you, David, for the question. The primary element that that was in play earlier in the year was we were just behind on hiring. And it relates to the tight labor market, where we just experienced some delays in hiring in the professional services staffing arena. And so we had existing commitments, and that meant we needed to ask our team members to stretch a little beyond what we would view from a Health Catalyst perspective to be a really sustainable utilization level. And so we are sensitive to that. We have partially caught up from a hiring perspective, as we shared in the prepared remarks earlier. And so that utilization, combined with the other major factors that Bryan shared around the mix of services that we are providing and some other factors as well are what we watch and what contributed to kind of where we find ourselves today.

Okay. And then in terms of like projects that are in the pipeline and expected utilization rates or billed hours per week per consultant, would you expect – I mean would you expect like, say, an 80% utilization rate in 2022? Just like any thoughts on like the margin profile per individual and expectations into 2022 would be very helpful.

Yes. Thanks, David. Yes. So, as I have mentioned, we are not quite ready to provide specific guidance and color on 2022 professional services gross margin, but the main factors that contribute to that margin profile are this item that you are referring to. So, the utilization rate of our team members is a primary factor. And we are hoping that, that continues to stay at a normal level going into next year. But there are other factors as well, including the mix of services provided, and we will have a better sense of that given that it can fluctuate on a quarterly basis as we get through our Q4 bookings performance and assess what services we are selling there as well as our first half 2022 sales pipeline and the mix of services that, that represents. And so those are two of the main factors that will play into that, and we will provide updates on that as we get through that data set in terms of the mix profile.

Okay, great. Thanks very much. Congrats on a good quarter.

Thank you. This does conclude the question-and-answer session of today’s program. I would like to hand the program back to Dan Burton for any further remarks.

Thank you all for your continued involvement and interest in Health Catalyst. And we look forward to staying in touch in the months ahead. Take care, everyone.

Thank you, ladies and gentlemen, for your participation in today’s conference. This does conclude the program. You may now disconnect. Good day.